Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition
- 10 May 2016
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (14), 1676-1688
- https://doi.org/10.1200/jco.2015.63.8049
Abstract
Purpose Non–small-cell lung cancer (NSCLC) is globally prevalent and associated with high rates of mortality. Immune checkpoint pathways are often exploited by tumors to evade immunity-mediated destruction, and checkpoint inhibitors can reactivate tumor-related immune responses. This review considers available clinical evidence for the use of checkpoint inhibitors in the treatment of second-line advanced NSCLC. Methods Our systematic search revealed 20 clinical trials evaluating checkpoint inhibitors in the second-line setting, three of which were randomized trials comparing programmed cell death protein 1 and programmed death ligand 1 (PD-L1) inhibitors to docetaxel, the current standard of care in this setting. Results A randomized phase II trial comparing the PD-L1 inhibitor atezolizumab to docetaxel did not demonstrate improved survival for atezolizumab in patients overall, although a trend toward improved survival with increased PD-L1 expression was apparent. Twin phase III trials showed significantly improved survival for the programmed cell death protein 1 inhibitor nivolumab compared with docetaxel in patients with both squamous and nonsquamous disease. PD-L1 expression correlated with improved survival in patients with nonsquamous disease, and patients with low levels of PD-L1 expression (< 10%) and those with EGFR mutations are unlikely to benefit. Checkpoint inhibitor therapy is generally well tolerated and associated with low rates of grade 3 or 4 adverse events compared with standard care. Conclusion Level 1 evidence exists to support the use of nivolumab as second-line treatment of patients with squamous advanced NSCLC, as well as in select patients with nonsquamous disease. Benefits remain unknown in patients with targetable driver mutations, and use of PD-L1 expression to guide therapy remains controversial. Results from ongoing randomized trials evaluating biomarkers and other checkpoint inhibitors will further our understanding of this rapidly evolving area of oncology.Keywords
This publication has 47 references indexed in Scilit:
- Maintenance Treatment With Different Strategies in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-AnalysisClinical Lung Cancer, 2013
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase InhibitorsArchives of Pathology & Laboratory Medicine, 2013
- New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical TrialsJournal of Clinical Oncology, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II StudyJournal of Clinical Oncology, 2012
- Positive and Negative Regulation of Cellular Immune Responses in Physiologic Conditions and DiseasesClinical and Developmental Immunology, 2012
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaJournal of Translational Medicine, 2011
- Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumabProceedings of the National Academy of Sciences, 2011
- Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their ManagementSeminars in Oncology, 2010
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996